Ignite Creation Date:
2024-05-06 @ 3:46 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04757259
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2024-03-19
First Post:
2021-02-10
Brief Title:
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
Sponsor:
Alexion Pharmaceuticals Inc
Organization:
Alexion Pharmaceuticals Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Non-hodgkins Lymphoma |
| RelapsedRefractory Chronic Lymphocytic Leukemia |
Keywords: